In the population of patients with known molecular factors patients the median survival in those with an IDH mutated GBM was 56.0 months (95% CI: 32.5–79.5); whilst those with MGMT methylation was 28.0 months (95% CI: 17.6–38.4). This evidence concerns the gene MGMT and glioblastoma.